Oxelumab

Drug Profile

Oxelumab

Alternative Names: Anti-OX40L - Genentech; huMAb OX40L; OX40L huMab; R4930; RG 4930; RO4989991; Roche 4

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Genentech; Genmab; Roche
  • Class Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action OX40 ligand inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Allergic asthma; Allergic rhinitis

Most Recent Events

  • 30 Jun 2011 Discontinued - Phase-I for Allergic rhinitis in USA (IV)
  • 30 Jun 2011 Discontinued - Phase-II for Allergic asthma in Canada (IV)
  • 30 Apr 2011 Roche completes a phase I trial in Allergic rhinitis in USA (NCT01152619)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top